Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WanburyBOM:524212 -2.68%67 Days Payable is 149.86 as of Mar. 2026, which is 21% below its 10-year median of 190.41. GuruFocus rates BOM:524212 with a GF Score™ of 67/100 and a GF Value™ of ₹244.17 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Wanbury ranks better than 76.91% on this metric.
Wanbury's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹1,072 Mil. Wanbury's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹653 Mil.
Hence, Wanbury's Days Payable for the
three
months ended in Mar. 2026 was 149.86.
The historical rank and industry rank for Wanbury's Days Payable or its related term are showing as below:
BOM:524212'
s Days Payable Range Over the Past 10 Years
Min: 157.64 Med: 190.41 Max: 238.34
Current: 157.64
During the past 13 years, Wanbury's highest Days Payable was 238.34. The lowest was 157.64. And the median was 190.41.
BOM:524212's Days Payable is ranked better than 76.91% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.16
vs BOM:524212: 157.64
Wanbury's Days Payable
increased
from Mar. 2025 (149.84) to Mar. 2026 (149.86).
It may suggest that Wanburydelayed paying its suppliers.
The historical data trend for Wanbury's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wanbury's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanbury Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wanbury's Days Payable distribution charts can be found below:
* The bar in red indicates where Wanbury's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Wanbury's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wanbury (BOM:524212) has a Days Payable of 149.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wanbury and its competitors. This is 21% below median its historical median of 190.41. Over the past decade, Wanbury's Days Payable has ranged from 157.64 to 238.34. According to the industry distribution chart, Wanbury ranks #214 out of 927 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Wanbury's Days Payable too high?
Wanbury's current Days Payable of 149.86 is 21% below median its 10-year median of 190.41. Over the past 10 years, this metric has ranged from a low of 157.64 to a high of 238.34. The Drug Manufacturers industry median Days Payable is 90.16. Wanbury's value of 149.86 is 66.2% above this industry median. Based on the distribution chart, Wanbury ranks #214 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wanbury has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wanbury's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wanbury ranks #214 out of 927 companies for Days Payable. This places Wanbury in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.16. Wanbury's value of 149.86 is 66.2% above this benchmark. Historically, Wanbury's own Days Payable has ranged from 157.64 to 238.34 over the past decade. While the company's 10-year median is 190.41 vs. the industry median of 90.16, Wanbury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.16, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wanbury's current Days Payable of 149.86 is 66.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wanbury and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanbury's current Days Payable is 149.86, which is 21% below median its own 10-year median of 190.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanbury stock overvalued right now?
Based on GuruFocus' analysis, Wanbury (BOM:524212) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹244.17, compared to a current price of ₹279.10 — trading 14.3% above its estimated fair value. The current Days Payable is 149.86, which is 21% below median its 10-year median of 190.41 and 66.2% above the Drug Manufacturers industry median of 90.16. Wanbury's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wanbury (BOM:524212), the current Days Payable is 149.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanbury (BOM:524212) Overvalued in 2026?
Based on GuruFocus' analysis, Wanbury stock appears to be overvalued.
The current stock price of ₹279.10 is trading 14.3% above its estimated GF Value™ of ₹244.17.
GuruFocus considers Wanbury to be Modestly Overvalued.
Key valuation signals for BOM:524212:
Days Payable: 149.86 (21% below median its 10-year median of 190.41)
GF Value™: ₹244.17 vs. price of ₹279.10 (14.3% above fair value)
Industry Position: 66.2% above the Drug Manufacturers median (#214 of 927)
No single metric tells the full story. See the BOM:524212 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
67GF Score
Get the complete analysis for BOM:524212
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524212 has been successfully added to your 
